Vir Biotechnology (VIR) to Release Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR - Get Free Report) is projected to announce its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.85) per share and revenue of $8.14 million for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

Vir Biotechnology Price Performance

Shares of VIR stock traded down $0.23 during trading hours on Friday, reaching $9.57. 712,701 shares of the company were exchanged, compared to its average volume of 1,185,198. Vir Biotechnology has a fifty-two week low of $6.56 and a fifty-two week high of $14.45. The stock's fifty day moving average is $9.31 and its two-hundred day moving average is $8.48. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -2.44 and a beta of 0.64.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of Vir Biotechnology stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total transaction of $137,219.20. Following the transaction, the director now directly owns 1,312,391 shares in the company, valued at approximately $16,431,135.32. The trade was a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director George A. Scangos sold 10,964 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now directly owns 708,295 shares of the company's stock, valued at approximately $6,948,373.95. The trade was a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,562 shares of company stock worth $259,693. 15.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

VIR has been the subject of a number of recent research reports. Morgan Stanley upgraded Vir Biotechnology from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. Barclays reduced their target price on shares of Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. Leerink Partners lifted their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. JPMorgan Chase & Co. increased their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a report on Thursday, January 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a report on Friday, January 31st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $34.83.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).